- Home
- OPK vs COLL Comparison
OPK vs COLL Comparison
Compare OPK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPK | COLL |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.2M | 1.2B |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OPK | COLL |
|---|---|---|
| Price | $1.12 | $32.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $2.03 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 2.5M | 547.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | $606,879,000.00 | ★ $780,567,000.00 |
| Revenue This Year | N/A | $5.93 |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | $19.32 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $1.10 | $23.23 |
| 52 Week High | $1.69 | $50.79 |
Technical Indicators
Market Signals| Indicator | OPK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 24.32 |
| Support Level | $1.12 | $31.01 |
| Resistance Level | $1.27 | $32.92 |
| Average True Range (ATR) | 0.04 | 1.30 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 20.83 | 1.07 |
Price Performance
Historical ComparisonAbout OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.